BioNTech SE (NASDAQ:BNTX) Shares Sold by Bronte Capital Management Pty Ltd.

Bronte Capital Management Pty Ltd. decreased its position in shares of BioNTech SE (NASDAQ:BNTX) by 0.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,364 shares of the company’s stock after selling 135 shares during the quarter. BioNTech accounts for approximately 0.2% of Bronte Capital Management Pty Ltd.’s portfolio, making the stock its 24th largest holding. Bronte Capital Management Pty Ltd.’s holdings in BioNTech were worth $2,466,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC grew its stake in BioNTech by 6.9% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,711 shares of the company’s stock valued at $186,000 after acquiring an additional 111 shares during the period. Sectoral Asset Management Inc. increased its position in shares of BioNTech by 3.5% during the third quarter. Sectoral Asset Management Inc. now owns 3,445 shares of the company’s stock worth $374,000 after purchasing an additional 116 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in BioNTech by 3.9% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company’s stock valued at $432,000 after purchasing an additional 148 shares during the last quarter. CWM LLC grew its stake in BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after acquiring an additional 217 shares in the last quarter. Finally, Midwest Professional Planners LTD. lifted its stake in BioNTech by 8.5% in the 3rd quarter. Midwest Professional Planners LTD. now owns 2,822 shares of the company’s stock worth $307,000 after purchasing an additional 220 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Up 2.1 %

NASDAQ BNTX traded up $1.93 on Thursday, hitting $92.06. 581,675 shares of the stock traded hands, compared to its average volume of 653,277. BioNTech SE has a twelve month low of $85.21 and a twelve month high of $125.83. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $21.89 billion, a P/E ratio of 21.88 and a beta of 0.25. The stock has a 50-day moving average of $90.47 and a 200 day moving average of $95.95.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. As a group, analysts expect that BioNTech SE will post -1.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. HC Wainwright increased their target price on shares of BioNTech from $107.00 to $113.00 and gave the stock a “buy” rating in a research note on Wednesday. TD Cowen upped their price target on BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research note on Tuesday. BMO Capital Markets reduced their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday. The Goldman Sachs Group reduced their price target on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. cut their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a report on Friday, March 22nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, BioNTech currently has an average rating of “Hold” and an average price target of $118.82.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.